314d0522
2021-04-11
[微笑]
EU seeks new contract with Pfizer/BioNTech for up to 1.8 billion vaccines from 2022 -EU source
免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。
分享至
微信
复制链接
精彩评论
我们需要你的真知灼见来填补这片空白
打开APP，发表看法
APP内打开
发表看法
2
2
{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":346734060,"tweetId":"346734060","gmtCreate":1618111322350,"gmtModify":1634294854442,"author":{"id":3575672525273340,"idStr":"3575672525273340","authorId":3575672525273340,"authorIdStr":"3575672525273340","name":"314d0522","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":5,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[微笑] </span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[微笑] </span><br></p></body></html>","text":"[微笑]","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/346734060","repostId":2126038125,"repostType":4,"repost":{"id":"2126038125","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1617981432,"share":"https://www.laohu8.com/m/news/2126038125?lang=&edition=full","pubTime":"2021-04-09 23:17","market":"us","language":"en","title":"EU seeks new contract with Pfizer/BioNTech for up to 1.8 billion vaccines from 2022 -EU source","url":"https://stock-news.laohu8.com/highlight/detail?id=2126038125","media":"Reuters","summary":"BRUSSELS, April 9 (Reuters) - The European Commission is seeking EU governments’ approval to launch ","content":"<p>BRUSSELS, April 9 (Reuters) - The European Commission is seeking EU governments’ approval to launch talks with Pfizer and BioNTech for the purchase of up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, an EU official told Reuters.</p>\n<p>Earlier on Friday, German daily Die Welt reported that the Commission was shortly to sign contracts to buy up to 1.8 billion doses, but did not say with which company.</p>\n<p>The EU official, who asked not to be named because the matter is confidential, said the EU executive had already decided to approach Pfizer-BioNTech and that EU governments backed the plan, though there was not yet a definitive approval.</p>\n<p>A Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.</p>\n<p>He also confirmed that the EU executive had already identified one supplier, a manufacturer of mRNA vaccines, but declined to comment on which company would be approached to negotiate the contract.</p>\n<p>“If provided the opportunity Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.</p>\n<p>The two companies have the capacity to produce more than 3 billion doses of vaccine in 2022, he added.</p>\n<p>Pfizer-BioNTech and Moderna are already supplying the EU with mRNA vaccines and German biotech firm CureVac is seeking EU approval for its mRNA shot.</p>\n<p>The vaccines would be delivered under monthly timetables and with clauses obliging the supplier to deliver, the EU official said.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EU seeks new contract with Pfizer/BioNTech for up to 1.8 billion vaccines from 2022 -EU source</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEU seeks new contract with Pfizer/BioNTech for up to 1.8 billion vaccines from 2022 -EU source\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-04-09 23:17</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BRUSSELS, April 9 (Reuters) - The European Commission is seeking EU governments’ approval to launch talks with Pfizer and BioNTech for the purchase of up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, an EU official told Reuters.</p>\n<p>Earlier on Friday, German daily Die Welt reported that the Commission was shortly to sign contracts to buy up to 1.8 billion doses, but did not say with which company.</p>\n<p>The EU official, who asked not to be named because the matter is confidential, said the EU executive had already decided to approach Pfizer-BioNTech and that EU governments backed the plan, though there was not yet a definitive approval.</p>\n<p>A Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.</p>\n<p>He also confirmed that the EU executive had already identified one supplier, a manufacturer of mRNA vaccines, but declined to comment on which company would be approached to negotiate the contract.</p>\n<p>“If provided the opportunity Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.</p>\n<p>The two companies have the capacity to produce more than 3 billion doses of vaccine in 2022, he added.</p>\n<p>Pfizer-BioNTech and Moderna are already supplying the EU with mRNA vaccines and German biotech firm CureVac is seeking EU approval for its mRNA shot.</p>\n<p>The vaccines would be delivered under monthly timetables and with clauses obliging the supplier to deliver, the EU official said.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2126038125","content_text":"BRUSSELS, April 9 (Reuters) - The European Commission is seeking EU governments’ approval to launch talks with Pfizer and BioNTech for the purchase of up to 1.8 billion doses of their COVID-19 vaccines to be delivered in 2022 and 2023, an EU official told Reuters.\nEarlier on Friday, German daily Die Welt reported that the Commission was shortly to sign contracts to buy up to 1.8 billion doses, but did not say with which company.\nThe EU official, who asked not to be named because the matter is confidential, said the EU executive had already decided to approach Pfizer-BioNTech and that EU governments backed the plan, though there was not yet a definitive approval.\nA Commission spokesman confirmed plans to buy the additional doses, of which half would be optional.\nHe also confirmed that the EU executive had already identified one supplier, a manufacturer of mRNA vaccines, but declined to comment on which company would be approached to negotiate the contract.\n“If provided the opportunity Pfizer and BioNTech are prepared to supply Europe with hundreds of millions of doses of COVID vaccines in 2022 and 2023 produced in our manufacturing facilities in Europe,” a Pfizer spokesman said.\nThe two companies have the capacity to produce more than 3 billion doses of vaccine in 2022, he added.\nPfizer-BioNTech and Moderna are already supplying the EU with mRNA vaccines and German biotech firm CureVac is seeking EU approval for its mRNA shot.\nThe vaccines would be delivered under monthly timetables and with clauses obliging the supplier to deliver, the EU official said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":1126,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/346734060"}
精彩评论